Last reviewed · How we verify
Carboplatin, etoposide & thalidomide
This combination uses carboplatin and etoposide as chemotherapy agents to damage cancer cell DNA, while thalidomide acts as an immunomodulator and anti-angiogenic agent to enhance anti-tumor immunity and inhibit blood vessel formation.
This combination uses carboplatin and etoposide as chemotherapy agents to damage cancer cell DNA, while thalidomide acts as an immunomodulator and anti-angiogenic agent to enhance anti-tumor immunity and inhibit blood vessel formation. Used for Multiple myeloma (phase 3 investigation).
At a glance
| Generic name | Carboplatin, etoposide & thalidomide |
|---|---|
| Sponsor | University College, London |
| Drug class | Combination chemotherapy with immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that cross-links DNA and prevents replication. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks. Thalidomide enhances T-cell proliferation and NK cell activation while inhibiting tumor necrosis factor-alpha and angiogenesis. Together, these agents provide multi-modal cytotoxic and immunomodulatory effects against cancer cells.
Approved indications
- Multiple myeloma (phase 3 investigation)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Neuropathy
- Nausea and vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |